How Long Is Your Plan Willing To Throw Away Thousands of Dollars Per Script For An MS Drug? ____________ Review your Plan’s most expensive therapeutic categories, and it’s virtually certain you’ll find multiple sclerosis drugs among those that are ringing up the largest tab for your Plan, even though it’s estimated that less than 1 million […]
If your Plan wants to decrease and control its costs, you need your PBM to take advantage of every Specialty Drug savings opportunity. Unfortunately, many – if not most – PBMs fail to do so. Zytiga, a high-cost treatment for metastasized prostate cancer, now has a far lower-cost generic substitute available, called abiraterone. Litigation hangs […]
Any Plan that wants to control its prescription coverage costs needs to control the “days supply” of Specialty Drugs that will be dispensed by its PBM. Your Plan can’t afford to squander precious money on Specialty Drugs that your Plan beneficiaries may never use and may instead flush down the toilet. Therefore, if you haven’t […]
We’re thrilled to report that yet another Coalition Member that followed our Coalition’s recommendations and took aggressive steps to control its prescription coverage costs has now achieved a 16% cost decrease.
Most health plans’ prescription coverage programs allow plan beneficiaries to purchase drugs at virtually all retail pharmacies in the United States, regardless of the prices charged by those pharmacies.
But in a time of spiraling drug costs, every health plan administrator should consider excluding either – or both – of two of the highest-cost chain pharmacies: CVS and Walgreens. Read this article to find out why.
You’ve undoubtedly heard that Turing Pharmaceuticals purchased a low-cost drug, Daraprim, and raised its cost by 5433% last year. And Turing’s smug CEO, Martin Shkreli, defended the price hike as perfectly reasonable. But are you aware that several other drug manufacturers are continually purchasing drugs and dramatically increasing their prices? And do you know that during the past 12 months the prices of almost 150 brand drugs increased by 100% or more?
Most important of all: Do you realize that as your Plan’s administrator, you can take steps to protect your Plan against some of these outrageous price increases? Read this article to learn how to do so.
Approximately 100 years ago, at the turn of the twentieth century, anyone could market any concoction claiming it solved any – or every – health problem. You may think that federal laws now prohibit the distribution of un-approved FDA drugs, but your assumption is dead wrong!
Moreover, you may have told your PBM – or insurer – that your health plan only covers FDA-approved drugs, but you are probably spending a small fortune for drugs that were never submitted to – let alone approved by – the FDA.
Drug prices were in the news this week because of a shocking 5000% increase in the cost of a single drug: Daraprim. But during the first 9 months of 2015, the average wholesale price (AWP) of almost 50 drugs more than tripled.
Given this striking fact, unless your plan – or Coalition – positions itself to learn about – and respond to – these steep price increases, as well as those that will inevitably occur in the future, your plan will not be able to control its costs. Read this article, to find out exactly how to do so.
The “Latest” Is Not Necessarily The “Greatest” When It Comes To Drugs
The drug marketplace is continually changing, and new drugs are continually entering the market.
But there’s good reason to act to prevent your plan beneficiaries from using many newly approved drugs.
Read this article and learn why doing so will often protect – not harm – your Plan Beneficiaries, as well as conserve your Plan assets. And why you can’t depend on the FDA – or your PBM – to accomplish those goals.
It’s critically important that every health plan monitor its claims data to determine whether pharmacy claims data errors are allowing your PBM to overcharge for drugs and misrepresent whether it satisfied your PBM contract’s financial guarantees.
Your PBM has every reason to ignore all claims data errors. And your auditor may do so as well! But your Plan can’t ignore these errors, if you expect to control your costs.
Careful monitoring of new clients’ claims data reveals an abundance of new, high cost Compound Drug creams that are causing Plans’ costs to soar. And many – if not most – of the new compound drugs have no proven efficacy!
Read this article to understand the problem, and learn exactly what you need to do to ensure these compound drugs don’t cost your Plan immense sums.